PHGUF (Pharming Group) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHGUF Pharming Group PHGUF
65 GF Score
Price $1.11
GF Value $1.02
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Pharming Group Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharming Group  (OTCPK:PHGUF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharming Group Cyclically Adjusted PB Ratio Related Terms


Pharming Group Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Pharming Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Cyclically Adjusted PB Ratio Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.84 6.93 5.93 4.32 6.25

Pharming Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.04 6.28 6.71 5.90 4.34

PHGUF vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted PB Ratio falls into.


PHGUF
65GF Score
Pharming Group PHGUF
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharming Group's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pharming Group's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.363/137.7000*137.7000
=0.363

Current CPI (Jun. 2026) = 137.7000.

Pharming Group Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.041 100.570 0.056
201612 0.064 100.710 0.088
201703 0.065 101.440 0.088
201706 0.016 101.370 0.022
201709 0.014 102.030 0.019
201712 0.039 101.970 0.053
201803 0.065 102.470 0.087
201806 0.078 103.100 0.104
201809 0.091 103.950 0.121
201812 0.114 103.970 0.151
201903 0.125 105.370 0.163
201906 0.141 105.840 0.183
201909 0.157 106.700 0.203
201912 0.186 106.800 0.240
202003 0.200 106.850 0.258
202006 0.225 107.510 0.288
202009 0.250 107.880 0.319
202012 0.286 107.850 0.365
202103 0.292 108.870 0.369
202106 0.307 109.670 0.385
202109 0.303 110.790 0.377
202112 0.297 114.010 0.359
202203 0.299 119.460 0.345
202206 0.306 119.050 0.354
202209 0.307 126.890 0.333
202212 0.312 124.940 0.344
202303 0.304 124.720 0.336
202306 0.304 125.830 0.333
202309 0.320 127.160 0.347
202312 0.326 126.450 0.355
202403 0.307 128.580 0.329
202406 0.309 129.910 0.328
202409 0.333 131.610 0.348
202412 0.325 131.630 0.340
202503 0.316 133.330 0.326
202506 0.332 133.960 0.341
202509 0.386 135.920 0.391
202512 0.395 135.470 0.402
202603 0.383 136.840 0.385
202606 0.363 137.700 0.363

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharming Group (PHGUF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be overvalued. The current stock price of $1.11 is trading 8.3% above its estimated GF Value™ of $1.02. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHGUF:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $1.02 vs. price of $1.11 (8.3% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the PHGUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
65GF Score

Get the complete analysis for PHGUF

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.11
Price
$1.02
GF Value